Dermata Therapeutics Inc. Company Profile
NASDAQ: DRMAHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Dermata Therapeutics at a glance
Dermata Therapeutics Inc. (NASDAQ: DRMA) is a Biotechnology company in the Healthcare sector headquartered in San Diego, CA. Dermata Therapeutics is led by Mr. Gerald T. Proehl and employs about 9 people. The company's shares have traded publicly since 2021.
At a market capitalization of $5.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001853816, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Dermata Therapeutics do?
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Dermata Therapeutics Inc.
- Ticker
- NASDAQ: DRMA
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Gerald T. Proehl
- Employees
- 9
- Headquarters
- 3525 Del Mar Heights Rd., San Diego, CA, United States
- Phone
- 858 800 2543
- Website
- dermatarx.com
- IPO year
- 2021
- Market cap
- $5.30M
- SEC CIK
- 0001853816
- Latest annual report
- 10-K · Mar 26, 2026
Companies similar to Dermata Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CDIOCardio Diagnostics Holdings Inc. | 1.86 | -5.58% | $5.50M | vs DRMA |
| ENLVEnlivex Ltd. | 0.277 | -10.85% | $5.51M | vs DRMA |
| LNAILunai Bioworks Inc. | 1.12 | +2.75% | $5.08M | vs DRMA |
| ADXNAddex Therapeutics Ltd ADR | 3.18 | +6.81% | $5.57M | vs DRMA |
| PULMPulmatrix Inc. | 1.53 | +2.49% | $5.58M | vs DRMA |
| XBIOXenetic Biosciences Inc. | 2.12 | -4.07% | $4.97M | vs DRMA |
| LIMNLiminatus Pharma Inc. Class A | 3.69 | -4.65% | $4.96M | vs DRMA |
| XTLBXTL Biopharmaceuticals Ltd. ADR | 1.99 | +0.51% | $4.89M | vs DRMA |